---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-055881"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2023-07-10T23:59:59+00:00"
generated_at: "2026-06-13T10:33:23.559575+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adial Pharmaceuticals receives Nasdaq extension to regain minimum equity compliance; equity $1.44M vs $2.5M required

## Summary
- Nasdaq granted extension until August 21, 2023 to file Form 10-Q to show compliance with Listing Rule 5550(b)(1).
- As of March 31, 2023, stockholders' equity was $1,439,848, below the $2,500,000 minimum.
- Compliance plan submitted June 28, 2023; expects to regain compliance upon Q2 10-Q filing.
- If compliance not regained, Company can request a hearing; listing may be suspended or delisted.
- Company monitoring equity and may consider further options to regain compliance.

## SEC filing metadata
- accession: 0001213900-23-055881
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2023-07-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390023055881/0001213900-23-055881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390023055881/ea181585-8k_adialpharm.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-055881
- JSON: https://secwatch.observer/filing/0001213900-23-055881.json
- Plain text: https://secwatch.observer/filing/0001213900-23-055881.txt

## Key facts
- Listing & Compliance Notices
  ADIAL PHARMACEUTICALS, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: July 7, 2023, Adial Pharmaceuticals, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that the Company had been granted an extension up until August 21, 2023 to file a Form 10-Q Report for the period ended June 30, 2023 evidencing compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”). On May 19, 2023, the Company had received a letter from Nasdaq stating that the Company was not in compliance with the Rule because the stockholders’ equity of the Company of $1,439,848 as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q fil
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023055881/0001213900-23-055881-index.htm
- Listing & Compliance Notices
  ADIAL PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 19, 2023, the Company had received a letter from Nasdaq stating that the Company was not in compliance with the Rule because the stockholders’ equity of the Company of $1,439,848 as of March 31, 2023, as reported in the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 12, 2023, was below the minimum requirement of $2,500,000. The notification received has no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. Pursuant to Nasdaq’s Listing Rules, the Company had 4
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023055881/0001213900-23-055881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.